LG to supply new antidiabetic agent to Turkey

Published: 2010-11-12 06:59:00

Updated: 2010-11-12 06:59:00

LG Life Sciences Ltd. has signed a contract with Turkey based NOBEL Ilac for the development and export for LC15-0444, an oral dipeptidyl peptidase IV (DPP IV) inhibitor, for the treatment of type II diabetes, said the pharmaceutical division of LG Group on November 10.

Under the agreement, L...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK